cosmin4000/iStock by way of Getty Photographs
- Omeros Company (NASDAQ:OMER) mentioned on Tuesday that the U.S. FDA has accepted the resubmitted label growth utility for narsoplimab, a remedy for transplant-associated thrombotic microangiopathy, which may happen after stem cell transplants.
- The biologics license utility resubmission is classed as
Source link
#Omeros #FDA #acceptance #narsoplimab #BLA #resubmission
